Riverbridge Partners LLC Has $46.68 Million Holdings in U.S. Physical Therapy, Inc. (USPH)

Share on StockTwits

Riverbridge Partners LLC decreased its holdings in shares of U.S. Physical Therapy, Inc. (NYSE:USPH) by 3.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 456,038 shares of the company’s stock after selling 17,442 shares during the period. Riverbridge Partners LLC owned 3.59% of U.S. Physical Therapy worth $46,675,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in USPH. Harvest Fund Management Co. Ltd bought a new stake in shares of U.S. Physical Therapy during the third quarter valued at approximately $190,000. Ibex Investors LLC bought a new stake in shares of U.S. Physical Therapy during the third quarter valued at approximately $207,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of U.S. Physical Therapy during the second quarter valued at approximately $219,000. PNC Financial Services Group Inc. increased its position in shares of U.S. Physical Therapy by 62.7% during the second quarter. PNC Financial Services Group Inc. now owns 2,676 shares of the company’s stock valued at $256,000 after acquiring an additional 1,031 shares in the last quarter. Finally, BlueMountain Capital Management LLC increased its position in shares of U.S. Physical Therapy by 54.3% during the second quarter. BlueMountain Capital Management LLC now owns 2,691 shares of the company’s stock valued at $258,000 after acquiring an additional 947 shares in the last quarter. 99.53% of the stock is owned by institutional investors and hedge funds.

NYSE:USPH traded down $3.69 during trading hours on Monday, reaching $103.04. The company had a trading volume of 86,308 shares, compared to its average volume of 97,675. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.26. U.S. Physical Therapy, Inc. has a 52 week low of $71.70 and a 52 week high of $129.65. The company has a market cap of $1.37 billion, a PE ratio of 49.54, a price-to-earnings-growth ratio of 3.47 and a beta of 1.28.

U.S. Physical Therapy (NYSE:USPH) last posted its earnings results on Thursday, November 1st. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.06. The business had revenue of $113.10 million during the quarter, compared to the consensus estimate of $112.79 million. U.S. Physical Therapy had a net margin of 5.58% and a return on equity of 17.64%. The company’s revenue for the quarter was up 9.8% on a year-over-year basis. Research analysts forecast that U.S. Physical Therapy, Inc. will post 2.55 earnings per share for the current year.

In other news, CFO Lawrance W. Mcafee sold 3,100 shares of U.S. Physical Therapy stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $113.29, for a total transaction of $351,199.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mark J. Brookner sold 500 shares of U.S. Physical Therapy stock in a transaction on Friday, November 16th. The stock was sold at an average price of $118.50, for a total transaction of $59,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 5,600 shares of company stock worth $637,949 in the last quarter. Corporate insiders own 2.50% of the company’s stock.

A number of equities research analysts have commented on USPH shares. TheStreet downgraded shares of U.S. Physical Therapy from a “b” rating to a “c+” rating in a research report on Friday, November 2nd. Cantor Fitzgerald lifted their target price on shares of U.S. Physical Therapy from $103.00 to $107.00 and gave the stock a “neutral” rating in a research report on Friday, November 2nd. Four research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $113.67.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Zolmax and is the sole property of of Zolmax. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://zolmax.com/investing/riverbridge-partners-llc-has-46-68-million-holdings-in-u-s-physical-therapy-inc-usph/2824380.html.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.

Featured Story: How to use beta for portfolio diversification

Want to see what other hedge funds are holding USPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for U.S. Physical Therapy, Inc. (NYSE:USPH).

Institutional Ownership by Quarter for U.S. Physical Therapy (NYSE:USPH)

Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Scorpio Bulkers  Downgraded by Zacks Investment Research to “Strong Sell”
Scorpio Bulkers Downgraded by Zacks Investment Research to “Strong Sell”
Head-To-Head Survey: Cango  versus Microsoft
Head-To-Head Survey: Cango versus Microsoft
Reviewing Artemis Therapeutics  & Platform Specialty Products
Reviewing Artemis Therapeutics & Platform Specialty Products
Ferrellgas Partners  Downgraded to Sell at Zacks Investment Research
Ferrellgas Partners Downgraded to Sell at Zacks Investment Research
BioDelivery Sciences International  Lowered to “Hold” at Zacks Investment Research
BioDelivery Sciences International Lowered to “Hold” at Zacks Investment Research
Nord/LB Analysts Give Wacker Chemie  a €96.00 Price Target
Nord/LB Analysts Give Wacker Chemie a €96.00 Price Target


Leave a Reply

 
© 2006-2019 Zolmax.